Personalized Medicine Summit
Thursday, September, 2nd, 2010
Astra Zeneca, Waltham, MA

For the last decade, the promise of personalized medicine seemed just over the horizon.  Biotechnology companies were pursuing the strategy of therapeutics tailored to specific patients having specific disease subtypes. All of this was predicated on diagnostics that enabled selection of the right patients for clinical trial, selecting the right patients for therapy, and monitoring patients once on therapy.  The ultimate goal was to eliminate trial and error medicine and the health and economic consequences.

Personalized medicine today has made incredible strides towards realizing how a test coupled to a therapy can work, clinically. This summit will focus on the implementation of personalized medicine from multiple dimensions.

Going forward, drug discovery, development, commercialization, clinical research, regulatory pathways, health informatics, and reimbursement will evolve, in part, based on personalized medicine breakthroughs. But there is little clarity around how personalized medicine will be implemented throughout the healthcare ecosystem.

Although much of the attention around personalized medicine has been devoted to oncology, this summit will generate discussion to infer how lessons learned in oncology can be applied to other chronic illnesses.

Confirmed speakers include:

Mara Aspinall, President and CEO, On-Q-ity, Inc.,

William Chin, Executive Dean for Research, Harvard Medical School,

Jeff Elton, Founder, Vice Chairman and CEO of KEW Group LLC

Harry Glorikian, Founder and Managing Partner, Scientia Advisors

Chris Hansen, Senior National Staff Counsel, American Civil Liberties Union (ACLU)

John Hennessy, Executive Director and General Manager, AstraZeneca

Laura Housman, Executive Director, Market Access and Pricing, Novartis

Ankit Mahadevia, Associate, Life Sciences, Atlas Venture 

John McDonough, Chief Executive Officer, T2 Biosystems

Imran Nasrullah, Chief Business Officer, MassBio

Kristin Pothier, Vice President, Health Advances

David Resnick, Partner and Co-Practice Group Leader, Patents, Nixon Peabody LLP

Lucienne Ronco, Global Head, Discovery Medicine, AstraZeneca

Laura Sullivan, VP of Reimbursement and Contracting, Genzyme Genetics

Sesha Tekur, PhD, Life Science Research-Cellomics, ThermoFisher Scientific

Bob Wassman, Chief Medical Officer, Helicos Biosciences

Bruce R. Zetter, Ph.D., Charles Nowiszewski Professor of Cancer Biology, Children’s Hospital Boston / Harvard Medical School

See the full agenda online.

Directions to AstraZeneca